The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant mFOLFOXFIRI after curative-intent resection of oligometastatic colorectal cancer: Phase II FANTASTIC trial.
 
Kozo Kataoka
Honoraria - Guardant Health; Lilly; Merck; Takeda
Research Funding - Nakatani Foundation; Sysmex
 
Takeshi Yamada
Research Funding - Taiho Oncology (Inst)
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shintaro Kanaka
No Relationships to Disclose
 
Takeshi Suto
No Relationships to Disclose
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yasumasa Takii
No Relationships to Disclose
 
Masayoshi Yasui
No Relationships to Disclose
 
Toshifumi Yamaguchi
Honoraria - MSD Oncology; Ono pharmaceutical., Co LTD
Consulting or Advisory Role - Daiichi Sankyo Company, Limited
 
Nobuhisa Matsuhashi
Honoraria - Abbott Japan; Alfresa Pharma Corporation; Amco; Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Eisai; Guardant Health; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Kirin; Lilly Japan; MC Medical; Merck KGaA; Miyarisan pharmaceutical; MSD; Novartis; Olympus Marketing, Inc.; Ono Pharmaceutical; Stryker; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Covidien (Inst); e-NA Biotec Inc. (Inst); EPS Corporation (Inst); JMS (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toray Industries (Inst)
 
Naoto Takase
No Relationships to Disclose
 
Kazuma Ito
No Relationships to Disclose
 
Adham Jurdi
Employment - Natera
Stock and Other Ownership Interests - Agenus; Iovance Biotherapeutics; natera; Verastem
 
Erik Spickard
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Arkarachai Fungtammasan
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masataka Ikeda
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - Asahi Kasei KK; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Otsuka; Pfizer; Taiho Pharmaceutical
 
Keita Mori
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Welby
 
Yukihide Kanemitsu
Honoraria - Covidien; Ethicon